Abbvie Inc

5 of its medicines lose their last listed patent or exclusivity between January 1, 2026 and December 31, 2027.

May 12, 2026Lexaproescitalopram oxalate
October 6, 2026Saphrisasenapine maleate
June 13, 2027Lumiganbimatoprost
November 24, 2027Acular LSketorolac tromethamine
December 23, 2027Lastacaftalcaftadine

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits